Imatinib is still recommended for frontline therapy for CML
Author:
Affiliation:
1. Department of Medicine and Comprehensive Cancer Center, The University of Chicago, Chicago, IL
Abstract
Publisher
American Society of Hematology
Subject
Hematology
Link
http://ashpublications.org/bloodadvances/article-pdf/2/24/3648/1554982/advances018614.pdf
Reference34 articles.
1. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience;Kantarjian;Blood,2012
2. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013
3. Is there a best TKI for chronic phase CML?;Larson;Blood,2015
4. Long-term outcomes of imatinib treatment for chronic myeloid leukemia;Hochhaus;N Engl J Med,2017
5. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants;Hehlmann;Leukemia,2017
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-10
2. Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm;Blood Cancer Journal;2023-03-15
3. Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles;Advances in Clinical Chemistry;2023
4. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT;American Journal of Hematology;2022-10-31
5. Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining;Frontiers in Oncology;2021-09-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3